{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-004129","form_type":"8-K","ticker":"ITGR","cik":"0001114483","company_name":"Integer Holdings Corp","filed_at":"2024-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.210555+00:00","generated_at":"2026-05-31T16:10:44.378617+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Integer Q2 2024 sales up 9% to $436M, GAAP EPS $0.88, adj. EPS $1.30; raises profit outlook","bullets":["Sales $436M (+9% YoY, organic +5%); GAAP net income $31M (+30%); adj. net income $45M (+17%).","GAAP diluted EPS $0.88 (+$0.17); non-GAAP adj. EPS $1.30 (+$0.16).","Adjusted EBITDA $91M, +19% YoY.","FY 2024 sales reaffirmed $1.735B-$1.770B (9%-11% growth); adj. op. income growth raised to 14%-21%.","Cardio & Vascular +11%, Cardiac Rhythm & Neuromodulation +9%, Advanced Surgical +4%; Electrochem down."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-004129","json":"https://secwatch.observer/filing/0001171843-24-004129.json","markdown":"https://secwatch.observer/filing/0001171843-24-004129.md","text":"https://secwatch.observer/filing/0001171843-24-004129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1114483/000117184324004129/0001171843-24-004129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1114483/000117184324004129/f8k_072424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T16:10:44.378617+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}